NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded to "Sell" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded NRx Pharmaceuticals from “hold” to “sell,” while other analysts remain more optimistic; the stock has an overall “Moderate Buy” rating and an average price target of $34.50.
• NRXP opened at $3.27 after falling 2.1%, with a market capitalization of approximately $118.5 million and a 52-week range of $1.62 to $5.05.
• The company reported a quarterly loss of $0.18 per share, missing estimates by $0.09, while revenue of $1.10 million fell short of the $1.33 million consensus forecast.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Saturday.

A number of other equities analysts also recently commented on the company. Weiss Ratings restated a "sell (d-)" rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 5th. HC Wainwright reiterated a "buy" rating on shares of NRx Pharmaceuticals in a report on Monday. D. Boral Capital reissued a "buy" rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a research report on Tuesday, May 5th. BTIG Research cut their price target on shares of NRx Pharmaceuticals to $10.00 and set a "buy" rating on the stock in a report on Friday, August 7th. Finally, Ascendiant Capital Markets lifted their price target on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a "buy" rating in a research report on Monday, April 27th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $34.50.

NRx Pharmaceuticals Stock Down 2.1%

NRXP stock opened at $3.27 on Friday. The company has a market cap of $118.47 million, a price-to-earnings ratio of -3.00 and a beta of 2.18. The business has a fifty day simple moving average of $3.80 and a 200-day simple moving average of $2.95. NRx Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $5.05.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.09). The company had revenue of $1.10 million during the quarter, compared to analysts' expectations of $1.33 million. As a group, analysts expect that NRx Pharmaceuticals will post -0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Ethos Financial Group LLC lifted its stake in shares of NRx Pharmaceuticals by 33.6% during the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company's stock worth $34,000 after purchasing an additional 4,000 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in shares of NRx Pharmaceuticals in the fourth quarter valued at about $107,000. Two Sigma Investments LP grew its stake in shares of NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company's stock valued at $173,000 after buying an additional 20,880 shares in the last quarter. State Street Corp raised its holdings in shares of NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company's stock valued at $236,000 after buying an additional 10,700 shares during the period. Finally, Bleakley Financial Group LLC purchased a new stake in shares of NRx Pharmaceuticals during the 4th quarter valued at about $318,000. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company's research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx's pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source